Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -64.15% | 20.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.15% | 20.94% | |||
| Cost of Revenue | -- | 79.86% | |||
| Gross Profit | -50.66% | 7.66% | |||
| SG&A Expenses | 42.08% | -9.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.80% | -7.82% | |||
| Operating Income | -79.75% | 28.04% | |||
| Income Before Tax | -825.94% | 118.90% | |||
| Income Tax Expenses | 120.08% | -2,977.78% | |||
| Earnings from Continuing Operations | -800.76% | 119.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -800.76% | 119.59% | |||
| EBIT | -79.75% | 28.04% | |||
| EBITDA | -80.45% | 26.89% | |||
| EPS Basic | -797.11% | 119.54% | |||
| Normalized Basic EPS | -57.34% | 13.67% | |||
| EPS Diluted | -809.41% | 119.20% | |||
| Normalized Diluted EPS | -60.19% | 15.20% | |||
| Average Basic Shares Outstanding | 0.57% | 0.23% | |||
| Average Diluted Shares Outstanding | -1.25% | 2.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||